After weeks of speculation that biopharma deal making would cool off, 2019 got off to a flying start as far as mergers-and-acquisitions (M&A) is concerned, thanks to two blockbuster transactions: Bristol-Myers Squibb’s planned $74 billion acquisition of Celgene, followed four days later by Eli Lilly’s planned $8 billion purchase of Loxo Oncology—a deal that quickly became the buzz of the J.P. Morgan 37th Healthcare Conference, held earlier this month in San Francisco.
{iframe}https://www.genengnews.com/a-lists/10-takeover-targets-to-watch-in-2019/?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20190128&ajs_uid=5901D8426578G1Y&oly_enc_id=5901D8426578G1Y&ajs_trait_oebid=9675B9130356B7S{/iframe}